NEW YORK (GenomeWeb News) – Abcodia and Oxford Gene Technology announced today that they will collaborate on the discovery and validation of biomarkers for the early detection of pancreatic cancer.
Under the alliance, Abcodia will provide access to samples from its serum biobank taken from individuals up to seven years before the diagnosis of pancreatic cancer. OGT said that it will apply its functional protein array platform and its Genefficiency microRNA profiling array to identify pancreatic cancer-specific biomarkers that could potentially be used as indicators of developing pancreatic cancer.
Financial and other terms of the alliance were not disclosed.